FOXO4-DRI

Purity: 99.785%

Batch #: FOX-10-601

Verified Potency: 11.97mg

$240.00

FOXO4-DRI is a cell-permeable senolytic peptide used in research on cellular senescence, p53-mediated apoptosis, and aging-related pathways.

Size

3rd-Party Janoshik Verification

Ships by Calculating...

Disclaimer

For Research Use Only. Not for human consumption or therapeutic treatment.

About FOXO4-DRI

FOXO4-DRI is a D-retro-inverso peptide designed to disrupt the FOXO4-p53 interaction that allows senescent cells to evade apoptosis. By blocking this critical protein-protein binding, FOXO4-DRI causes p53 nuclear exclusion and redirects it to mitochondria, selectively triggering apoptosis in senescent cells while leaving healthy cells unaffected. Research has demonstrated its ability to selectively clear senescent fibroblasts, restore tissue homeostasis, and improve markers of aging in multiple mouse models. Scientists utilize FOXO4-DRI to investigate senescence-driven pathologies, the FOXO4-p53 survival axis, and targeted senolytic strategies in aging and cellular biology research.

Product Specifications

FOXO4-DRI Lyophilized Powder in 3ml vial

Application

Senolytic, cellular senescence, and aging pathway research

Appearance

Solid, white powder in 3mL glass ampule

Chemical Formula

C228H388N86O64

CAS number

2460055-10-9

Molecular Weight

~5358.1 g/mol

FAQs

What is FOXO4-DRI peptide?

FOXO4-DRI is a D-retro-inverso peptide engineered to interfere with the FOXO4-p53 protein interaction in senescent cells. It consists of the retro-inverso sequence of the p53-binding domain of FOXO4, using D-amino acids arranged in reverse order to resist protease degradation while maintaining binding affinity. The peptide was first described by Baar et al. in a 2017 study published in Cell, where it was shown to selectively induce apoptosis in senescent cells without affecting healthy cells.

What is FOXO4-DRI researched for?

FOXO4-DRI is studied as a senolytic agent, meaning it selectively eliminates senescent cells that accumulate with age and contribute to tissue dysfunction. Research published in Cell demonstrates that FOXO4-DRI restores fitness, fur density, and renal function in both fast-aging and naturally aged mice. The peptide is also investigated in the context of cellular senescence pathways, the DNA damage response, and age-related tissue deterioration across multiple organ systems.

How does FOXO4-DRI selectively target senescent cells?

Senescent cells rely on elevated FOXO4 expression to sequester p53 in the nucleus, preventing p53 from translocating to mitochondria and triggering apoptosis. FOXO4-DRI competitively disrupts this FOXO4-p53 interaction by binding p53 with higher affinity than endogenous FOXO4. Once displaced, p53 is excluded from the nucleus and redirected to mitochondria, where it activates the intrinsic apoptotic pathway. Because non-senescent cells do not depend on FOXO4-mediated p53 sequestration for survival, the peptide exhibits selectivity for senescent cells.

Has FOXO4-DRI been studied in animal models of aging?

Yes. In the original 2017 Cell publication, FOXO4-DRI was administered to both genetically fast-aging mice and naturally aged wild-type mice. Treated animals showed measurable improvements in markers of senescence-associated tissue decline, including restored renal tubular function and increased activity levels. The study also demonstrated that FOXO4-DRI neutralized doxorubicin-induced chemotoxicity in vivo, reducing liver damage caused by therapy-induced senescence.

Can I buy FOXO4-DRI peptide for research?

Limitless Peptides sells FOXO4-DRI as a lyophilized powder in a sealed 3mL glass ampule. Each vial contains 10mg of peptide manufactured in a GMP-standard facility and independently tested by Janoshik, a third-party analytical laboratory. A certificate of analysis with batch-specific purity and potency data is published on the product page. FOXO4-DRI is sold strictly for laboratory research use.

FOXO4-DRI

About FOXO4-DRI

FAQs

Related Peptides